Cargando…
Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
Checkpoint blockade immunotherapies have revolutionised cancer treatment in the last decade. Nevertheless, these are only beneficial for a small proportion of cancer patients. Important prognosticators for response to immunotherapy are the mutation burden of tumours as well as the quality and quanti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317065/ https://www.ncbi.nlm.nih.gov/pubmed/30191683 http://dx.doi.org/10.1002/cjp2.113 |
_version_ | 1783384677100290048 |
---|---|
author | Ijsselsteijn, Marieke E Brouwer, Thomas P Abdulrahman, Ziena Reidy, Eileen Ramalheiro, Ana Heeren, A Marijne Vahrmeijer, Alexander Jordanova, Ekaterina S de Miranda, Noel FCC |
author_facet | Ijsselsteijn, Marieke E Brouwer, Thomas P Abdulrahman, Ziena Reidy, Eileen Ramalheiro, Ana Heeren, A Marijne Vahrmeijer, Alexander Jordanova, Ekaterina S de Miranda, Noel FCC |
author_sort | Ijsselsteijn, Marieke E |
collection | PubMed |
description | Checkpoint blockade immunotherapies have revolutionised cancer treatment in the last decade. Nevertheless, these are only beneficial for a small proportion of cancer patients. Important prognosticators for response to immunotherapy are the mutation burden of tumours as well as the quality and quantity of tumour‐infiltrating immune cells. High‐throughput multiplex immunophenotyping technologies have a central role in deciphering the complexity of anti‐tumour immune responses. Current techniques for the immunophenotyping of solid tumours are held back by the lack of spatial context, limitations in the number of targets that can be visualised simultaneously, and/or cumbersome protocols. We developed a tyramide signal amplification‐free method for the simultaneous detection of seven cellular targets by immunofluorescence. This method overcomes limitations posed by most widespread techniques and provides a unique tool for extensive phenotyping by multispectral fluorescence microscopy. Furthermore, it can be easily implemented as a high‐throughput technology for validation of discovery sets generated by RNA sequencing or mass cytometry and may serve in the future as a complementary diagnostic tool. |
format | Online Article Text |
id | pubmed-6317065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63170652019-01-08 Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification Ijsselsteijn, Marieke E Brouwer, Thomas P Abdulrahman, Ziena Reidy, Eileen Ramalheiro, Ana Heeren, A Marijne Vahrmeijer, Alexander Jordanova, Ekaterina S de Miranda, Noel FCC J Pathol Clin Res Original Articles Checkpoint blockade immunotherapies have revolutionised cancer treatment in the last decade. Nevertheless, these are only beneficial for a small proportion of cancer patients. Important prognosticators for response to immunotherapy are the mutation burden of tumours as well as the quality and quantity of tumour‐infiltrating immune cells. High‐throughput multiplex immunophenotyping technologies have a central role in deciphering the complexity of anti‐tumour immune responses. Current techniques for the immunophenotyping of solid tumours are held back by the lack of spatial context, limitations in the number of targets that can be visualised simultaneously, and/or cumbersome protocols. We developed a tyramide signal amplification‐free method for the simultaneous detection of seven cellular targets by immunofluorescence. This method overcomes limitations posed by most widespread techniques and provides a unique tool for extensive phenotyping by multispectral fluorescence microscopy. Furthermore, it can be easily implemented as a high‐throughput technology for validation of discovery sets generated by RNA sequencing or mass cytometry and may serve in the future as a complementary diagnostic tool. John Wiley & Sons, Inc. 2018-12-04 /pmc/articles/PMC6317065/ /pubmed/30191683 http://dx.doi.org/10.1002/cjp2.113 Text en © 2018 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Ijsselsteijn, Marieke E Brouwer, Thomas P Abdulrahman, Ziena Reidy, Eileen Ramalheiro, Ana Heeren, A Marijne Vahrmeijer, Alexander Jordanova, Ekaterina S de Miranda, Noel FCC Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification |
title | Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification |
title_full | Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification |
title_fullStr | Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification |
title_full_unstemmed | Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification |
title_short | Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification |
title_sort | cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317065/ https://www.ncbi.nlm.nih.gov/pubmed/30191683 http://dx.doi.org/10.1002/cjp2.113 |
work_keys_str_mv | AT ijsselsteijnmariekee cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification AT brouwerthomasp cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification AT abdulrahmanziena cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification AT reidyeileen cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification AT ramalheiroana cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification AT heerenamarijne cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification AT vahrmeijeralexander cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification AT jordanovaekaterinas cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification AT demirandanoelfcc cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification |